(Q33657855)

28 July 2017

1 reference

title

Impact of drug therapy on benign prostatic hyperplasia-specific quality of life (English)

1 reference

28 July 2017

Rhodes PR

1

1 reference

28 July 2017

Krogh RH

series ordinal

2

1 reference

28 July 2017

Bruskewitz RC

series ordinal

3

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

53

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

1090-1098

1 reference

Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

The Natural History of Untreated “Prostatism”

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Quality of life in geriatric patients with lower urinary tract dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900041-2

7 January 2021

10.1016/S0090-4295(99)00041-2

Identifiers

DOI

1 reference

28 July 2017

1 reference